Bladder Cancer

Researchers from University of Turin detail new studies and findings in the area of bladder cancer

Published in Clinical Oncology Week, October 29th, 2007

"'Intravesical gemcitabine has been tested in several phase 1 studies. The 2000-mg dose of gemcitabine in 50 or 100 ml normal saline when administered intravesically for up to 2 h once a week for 6 wk has unremarkable systemic and local side effects; therefore, this schedule should be considered the most convenient," scientists writing in the journal European Urology Supplements report.

"Phase 2 studies have assessed the activity of intravesical gemcitabine on a marker lesion in intermediate-risk superficial bladder cancers (SBCs), showing complete responses in up to 60% of cases. Few attempts have been made to test the activity of intravesical gemcitabine in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2007-10-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry